Key result
Isolated cerebrovascular disease is linked to ~36% lower odds of receiving statins versus CAD alone.
Why the study?
It remains unclear whether patients' cardiovascular risk perceptions, cholesterol beliefs, or prescribed statin intensity differ among patients with CAD, CeVD, or both.
Does the intensity of prescribed statin therapy and LDL-C achievement differ for patients with cerebrovascular disease versus coronary artery disease?
Observational (n=3,232)
Yes
Does the intensity of prescribed statin therapy and LDL-C achievement differ for patients with cerebrovascular disease versus coronary artery disease?
Patients with cerebrovascular disease are significantly undertreated with statin therapy and less likely to achieve LDL-C goals compared to those with coronary artery disease, despite similar patient-perceived risks.
Answers are grounded in this paper and cite their sources.
CeVD-only patients may receive less intensive statin therapy than CAD patients despite similar beliefs; leaves open whether targeted quality efforts can close this gap.
Background Current treatment guidelines strongly recommend statin therapy for secondary prevention. However, it remains unclear whether patients' perceptions of cardiovascular risk, beliefs on cholesterol, or the intensity of prescribed statin therapy differs for patients with coronary artery disease (CAD) versus cerebrovascular disease (CeVD) versus both CAD and CeVD (CAD&CeVD). Methods and Results The PALM (Patient and Provider Assessment of Lipid Management) registry collected data on statin use, intensity, and core laboratory low-density lipoprotein cholesterol levels for 3232 secondary prevention patients treated at 133 US clinics. Among individuals with CeVD only (n=403), CAD only (n=2202), and CeVD&CAD (n=627), no significant differences were observed in patient-perceived cardiovascular disease risk, beliefs on cholesterol lowering, or perceived effectiveness and safety of statin therapy. However, patients with CeVD only were less likely to receive any statin therapy (76.2% versus 86.2%; adjusted odds ratio 0.64, 95% CI 0.45-0.91), or guideline-recommended statin intensity (34.6% versus 50.4%; adjusted odds ratio 0.60, 95% CI 0.45-0.81) than those with CAD only. Individuals with CeVD only were also less likely to achieve low-density lipoprotein cholesterol <100 mg/dL (59.2% versus 69.7%; adjusted odds ratio 0.79, 95% CI 0.64-0.99) than individuals with CAD alone. There were no significant differences in the use of any statin therapy or guideline-recommended statin intensity between individuals with CAD&CeVD and those with CAD only. Conclusions Despite lack of significant differences in patient-perceived cardiovascular risk or statin beliefs, patients with CeVD were significantly less likely to receive higher intensity statin or achieve low-density lipoprotein cholesterol <100 mg/dL than those with CAD only.
No takes yet. Share an insight, caveat, or question.
Xian et al. (2019) conducted an observational in Cerebrovascular Disease and Coronary Artery Disease (n=3,232). Cerebrovascular disease only vs. Coronary artery disease only was evaluated on Receipt of any statin therapy (adjusted OR 0.64, 95% CI 0.45-0.91). Patients with cerebrovascular disease only were less likely to receive any statin therapy than those with coronary artery disease only.
Synapse has enriched 10 related papers. Consider them for comparative context: